Thank you for donating!

You can donate using the following services.

How do you want to hear from us?

How do you want to hear from NPUK?

Even if you have previously told us how you would like to hear from us and/or you have supported us for many years, new data protection legislation requires you to provide your explicit consent in order for us to continue to contact you in the ways that are important to you.

Please use this form to tell us your preferences. You can also change your mind at any time – you will find further details about how to do this below. In the future, we will only contact you about the areas of our work you choose via the communication methods you prefer. Please complete all fields.

I would like to receive information about NPUK services, NPUK events, information and updates regarding the work of the Charity, including the NPUK Newsletter, in the following ways:

I would like to interact with the NPUK Care and Support Team, including the Clinical Nurse Specialist, Senior Families Advocate, Project Families Officer or Central Office Team. I give my consent for them to contact me in the following ways:

I would like to receive information and updates regarding research, clinical trials, treatment and care options relevant to Niemann-Pick disease, in the following ways:

I would like to receive information about NPUK Fundraising events and activities in the following ways:

I do not wish to hear from NPUK:

Your details

First name(s)


Address Line 1

Address Line 2

Address Line 3



Telephone - landline (include dialling code)

Telephone - mobile (include dialling code)

What is your connection to NPUK?


If you're under 16

Your age

Date of birth

Parent/guardian contact email

Parent/guardian contact telephone (include dailing code)

Do you have any additional comments?

Your Details Are Safe With Us – Privacy Statement:

We will always store your personal details securely. We will only use them to provide the service(s) that you have requested and communicate with you in the way(s) you have agreed to. Your details may also be used for analysis purposes, to help us provide the best possible service. We will not pass on your details to anyone else and we will only share them if required to do so by law.

Latest news



We are joining 140+ organisations in a call to all political parties to put children and young people at the heart of this General Election...

Read more


Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)

Kim Stratton, Chief Executive Officer at Orphazyme, commented, “We are delighted with FDA’s decision to grant Breakthrough Therapy Designation to arimoclomol for NPC. Arimoclomol has been shown to have a clinically meaningful effect on disease progression in NPC that is further supported by a biomarker effect indicating an effect on the biological underpinnings of the disease and a favorable safety and tolerability profile. We are committed to bringing this product to patients as soon as possible. Breakthrough Therapy Designation is designed to expedite the development and review of products for serious diseases with the direct involvement of senior staff and we look forward to working closely with the FDA to further advance arimoclomol. Our preparations for filing in the US are underway and we are on track to submit a New Drug Application in H1 2020.”

Read more
View all news Subscribe